Cboe Global (CBOE) Stock Gains 41% YTD: More Room for Growth?

view original post

Shares of Cboe Global Markets CBOE have gained 40.6% year to date compared with the industry and the Finance sector’s rally of 31.5% and 23.1%, respectively. The Zacks S&P 500 composite has increased 26% in the said time frame. With a market capitalization of about $14 billion, the average volume of shares traded in the last three months was 0.5 million.

Increased medium-term target, strong market position, global reach, strength in its proprietary products, and solid capital position continue to drive Cboe Global. It has a decent track of beating earnings estimates in all the three reported quarters of 2021.

– Zacks

Image Source: Zacks Investment Research

Return on equity in the trailing 12 months was 17.5%, better than the industry average of 13.5%.  

The Zacks Consensus Estimate for Cboe Global’s 2021 and 2022 earnings has moved up by 1 cent and 4 cents, respectively, in the past seven days, reflecting analysts’ optimism.

Can it Retain the Momentum?

The Zacks Consensus Estimate for 2021 indicates a year-over-year improvement of 9.5% on 15.6% higher revenues. The consensus estimate for 2022 indicates a year-over-year improvement of 2.9% on 3.9% higher revenues. It has an impressive Growth Score of B.

CBOE Global expects to deliver total net revenue growth of 5-7% annually, an increase from 4-6% growth expected earlier. While Cboe Global expects Data and Access Solutions to contribute organic net revenue growth of 7-10% annually over the medium term, derivatives initiatives will likely contribute 2-4% of total organic net revenue growth over the medium term. CBOE targets a medium-term return on invested capital of at least 10%.

CBOE Global’s growth strategy revolves around expanding its product, broadening geographic reach to highest value markets, diversifying business mix with recurring revenues, ramping up growth with recurring non-transaction revenues and leveraging technology. Cboe Global expects medium- to long-term organic total net revenue growth of 4-6%.

Cboe Global Markets boasts a compelling inorganic growth story. Recently, CBOE agreed to buy Aequitas Innovations in a bid to strengthen its North American presence. Acquisitions have expanded and diversified CBOE Global Markets’ product portfolio with U.S. and European cash equities, Global ETPs and Global FX, solid pan-European equities and global FX positions apart from strengthening its service portfolio and expanding geographically. Cboe Global estimates net revenue contribution from recent acquisitions in the range of 4% to 6%.

Being the largest stock exchange operator by volume in the United States and a leading market globally for ETP trading, this Zacks Rank #2 (Buy) company is accelerating non-transaction revenue growth. Cboe Global estimates recurring non-transactional organic revenue growth of 14% in 2021, up from 12-13% guided earlier.

Riding on a solid capital position, CBOE has hiked dividends each year since its IPO and increased the same by 14% in October 2021, marking the 11th consecutive year of dividend hike. It also has $318.9 million remaining under its existing share repurchase authorization.

Cboe Global is well poised for progress, evident from its favorable VGM Score of B. Here V stands for Value, G for Growth, and M for Momentum, with the score being a weighted combination of all three factors.

Other Stocks to Consider

Some other top-ranked stocks include OTC Markets Group OTCM, Intercontinental Exchange ICE and Athene Holding ATH.

OTC Markets Group sports a Zack Rank #1 (Strong Buy).  The Zacks Consensus Estimate for OTC Markets Group’s 2021 and 2022 has moved up 4.6% and 7.4% in the past seven days. The expected long-term earnings growth rate is pegged at 9%, in line with the industry average.

You can see the complete list of today’s Zacks #1 Rank stocks here.

Intercontinental Exchange carries a Zacks Rank #2. The Zacks Consensus Estimate for 2021 and 2022 earnings of Intercontinental Exchange implies 12.9% and 8.9% year-over-year growth, respectively.

Athene carries a Zacks Rank #2. The Zacks Consensus Estimate for 2021 earnings has moved up 9.9% in the past 30 days and implies 123.7% year-over-year growth. Athene delivered a four-quarter average earnings surprise of 46.12%.

OTCM, ICE and ATH have gained 72.1%, 14.7% and 96.5%, respectively, year to date.  

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Intercontinental Exchange Inc. (ICE): Free Stock Analysis Report

Cboe Global Markets, Inc. (CBOE): Free Stock Analysis Report

Athene Holding Ltd. (ATH): Free Stock Analysis Report

OTC Markets Group Inc. (OTCM): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Related Posts